{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-078742","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2022-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.806912+00:00","generated_at":"2026-06-21T06:59:38.602596+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Larkspur Health Acquisition Corp. stockholders approve ZyVersa merger; 7.7M shares redeemed","bullets":["Stockholders approved business combination with ZyVersa Therapeutics: 6,543,525 for, 785,791 against.","Approved charter amendments, 2022 Omnibus Incentive Plan, and Nasdaq issuance proposals.","7,667,029 shares tendered for redemption, ~76% of outstanding shares (10,029,221).","Special meeting held Dec 8, 2022; 73.08% quorum achieved."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-078742","json":"https://secwatch.observer/filing/0001213900-22-078742.json","markdown":"https://secwatch.observer/filing/0001213900-22-078742.md","text":"https://secwatch.observer/filing/0001213900-22-078742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022078742/0001213900-22-078742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022078742/ea169867-8k_larkspur.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:59:38.602596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"295d84b14952f2dcd8aa20ee522e4547c7852c55","claim":"ZyVersa Therapeutics, Inc. shareholders approved Approve exclusive forum provision for certain actions in Delaware courts. at the 2022-12-08 meeting.","evidence_excerpt":"Vote to approve the Forum Selection Proposal: Total Votes For Total Votes Against Abstentions 6,011,855 1,317,461 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022078742/0001213900-22-078742-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-08"}],"fact_type":"shareholder_vote"},{"claim_id":"4ccc2c664b07f8202288e692eb1392ad829683b6","claim":"ZyVersa Therapeutics, Inc. shareholders approved Approve increase in authorized capital stock to 111,000,000 shares. at the 2022-12-08 meeting.","evidence_excerpt":"Vote to approve the Authorized Shares Proposal: Total Votes For Total Votes Against Abstentions 6,526,282 803,034 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022078742/0001213900-22-078742-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-08"}],"fact_type":"shareholder_vote"},{"claim_id":"56604268e4ed20145ab5af7db114f92996c73077","claim":"ZyVersa Therapeutics, Inc. shareholders approved Approve amendment to require 66 2/3% vote to amend bylaws. at the 2022-12-08 meeting.","evidence_excerpt":"Vote to approve the Bylaws Amendment Proposal: Total Votes For Total Votes Against Abstentions 6,480,158 849,158 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022078742/0001213900-22-078742-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-08"}],"fact_type":"shareholder_vote"},{"claim_id":"5e21ee3030c025df4745d01990f35932800e544a","claim":"ZyVersa Therapeutics, Inc. shareholders approved Approve general amendments to charter including name change, purpose, removal of blank check provisions, and removal of stockholder action by written consent. at the 2022-12-08 meeting.","evidence_excerpt":"Vote to approve the General Amendments Proposal: Total Votes For Total Votes Against Abstentions 6,526,282 803,034 0 1","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022078742/0001213900-22-078742-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-08"}],"fact_type":"shareholder_vote"},{"claim_id":"6e400f7a28451cd89a2a84e7ff98b9bf05b744c9","claim":"ZyVersa Therapeutics, Inc. shareholders approved Approve amendment to set quorum at 33 1/3% of voting power. at the 2022-12-08 meeting.","evidence_excerpt":"Vote to approve the Quorum Standard Proposal: Total Votes For Total Votes Against Abstentions 6,526,283 803,033 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022078742/0001213900-22-078742-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-08"}],"fact_type":"shareholder_vote"},{"claim_id":"8b0f10aeb6ecdc33180379f59cc6c6294f1d1d24","claim":"ZyVersa Therapeutics, Inc. shareholders approved Approve adoption of Business Combination Agreement with ZyVersa Therapeutics, Inc. at the 2022-12-08 meeting.","evidence_excerpt":"Vote to approve the Business Combination Proposal: Total Votes For Total Votes Against Abstentions 6,543,525 785,791 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022078742/0001213900-22-078742-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"merger approval"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-08"}],"fact_type":"shareholder_vote"},{"claim_id":"b15fe130391ccd4c8732c2899ad5967bde3a36d4","claim":"ZyVersa Therapeutics, Inc. shareholders approved Approve amendment to require 66 2/3% vote to amend certain charter provisions. at the 2022-12-08 meeting.","evidence_excerpt":"Vote to approve the Supermajority Voting Standard Proposal: Total Votes For Total Votes Against Abstentions 6,480,157 849,159 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000121390022078742/0001213900-22-078742-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}